Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Maurice T. Driessen1*, Joshua M. Cohen2, Stephen F. Thompson3, Oscar Patterson-Lomba4, Michael J. Seminerio3, Karen Carr3, Todor I. Totev4, Rochelle Sun4, Erica Yim4, Fan Mu4 and Rajeev Ayyagari4

Abstract

Background: Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2aΔa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremanezumab for migraine prevention have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world effectiveness data are needed to complement clinical trial data. This study assessed the effectiveness of fremanezumab across different subgroups of adult patients with episodic migraine (EM), chronic migraine (CM), or difficult-to-treat (DTT) migraine in real-world clinical settings.

Methods: This retrospective, panel-based online chart review used electronic case report forms. Patient inclusion criteria were a physician diagnosis of EM or CM; age ≥ 18 years at the time of first fremanezumab initiation; ≥ 1 dose of fremanezumab treatment; ≥ 1 follow-up visit since first initiation; and ≥ 2 measurements of monthly migraine days (MMD; with 1 within a month before or at first initiation and ≥ 1 after first initiation). Changes in MMD and monthly headache days were assessed during the follow-up period. These endpoints were evaluated in subgroups of patients by migraine type (EM/CM) and in subgroups with DTT migraine (diagnosis of medication overuse [MO], major depressive disorder [MDD], generalized anxiety disorder [GAD], or prior exposure to a different CGRP pathway–targeted mAb [CGRP mAb]).

Results: Data were collected from 421 clinicians and 1003 patients. Mean (percent) reductions from baseline in MMD at Month 6 were −7.7 (77.0%) in EM patients, −10.1 (68.7%) in CM patients, −10.8 (80.6%) in the MO subgroup, −9.9 (68.3%) in the MDD subgroup, −9.5 (66.4%) in the GAD subgroup, and −9.0 (68.7%) in the prior CGRP mAb exposure subgroup. Improvements in MDD or GAD severity were reported by 45.5% and 45.8% of patients with comorbid MDD or GAD, respectively.

Conclusions: In this real-world study, fremanezumab demonstrated effectiveness for migraine regardless of migraine type or the presence of factors contributing to DTT migraine (MO, GAD, MDD, or prior exposure to a different CGRP mAb).
Introduction
Migraine is a prevalent, debilitating neurologic disease. In the United States alone, approximately 1 in 6 individuals suffer from migraine [1]. Migraine is the second leading cause of years lived with disability worldwide [2] and the leading cause of years lived with disability in individuals <50 years of age [3]. Patients with migraine experience significantly reduced health-related quality of life [4, 5] and work productivity [6]. Migraine results in >100 million lost workdays per year and is associated with >$75 billion in direct and indirect costs per year [7]. Within the migraine population, there are subgroups of patients who may have more difficult-to-treat (DTT) migraine based on prior migraine preventive treatment failure, acute medication overuse (MO), or the presence of psychiatric comorbidities, such as depression or anxiety. Patients with DTT migraine may experience more frequent headache days, more severe headache pain, increased disability, worse quality of life, and an increased risk for migraine chronification [8–12], resulting in increased health care resource utilization and cost burdens associated with migraine [13].

Fremanezumab is a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) ligand and is approved for the preventive treatment of migraine in adults [14]. Phase 3 randomized clinical studies up to 15 months have demonstrated the long-term efficacy and safety of quarterly and monthly fremanezumab in adults with episodic migraine (EM; 6–14 headache days per month) and chronic migraine (CM; ≥15 headache days per month), even those with DTT migraine [15–20].

To expand on the efficacy and safety data generated in phase 3 controlled clinical trial settings [15–20] and following the approval of fremanezumab in 2018 by the US Food and Drug Administration [14], real-world evidence is an important addition to confirm clinical effectiveness and adherence for fremanezumab treatment in patients with migraine, including those with DTT migraine. Therefore, in the current chart review, we evaluated the effectiveness of fremanezumab by migraine type (EM/CM) and among different subgroups of patients with potentially DTT migraine.

Methods
Study design
This US-based study was a non-interventional, retrospective, online, clinician panel–based chart review. The study design has been presented elsewhere and is briefly summarized here. Participating clinicians were provided a custom-designed electronic case report form (eCRF) to enter data abstracted from eligible patient charts. The eCRF was used to collect de-identified patient information, including demographic and clinical characteristics, prior treatment patterns, baseline migraine assessments, effectiveness outcomes during follow-up, and incidence of psychiatric comorbidities, for up to 5 patients meeting the inclusion criteria. Participating clinicians were asked to randomly select these patients’ charts using a randomization scheme that was included as part of the underlying program for the eCRF and was based on a randomized sequence of letters. Clinicians were asked to choose a patient chart with the last name corresponding to the random letter produced by the program; the program repeated this randomization process for each additional patient chart selected.

The date of first fremanezumab treatment initiation was designated as the index date.

Clinicant and patient eligibility criteria
Clinicians were selected to participate if they were a neurologist, general practitioner, pain management specialist, psychiatrist, physician assistant (PA), nurse practitioner (NP), or other headache specialist who routinely treated patients with EM or CM in a US-based practice and had treated ≥5 patients diagnosed with EM or CM in the past 12 months, including patients who met inclusion criteria. Eligible patients had a physician diagnosis of EM or CM; first initiation with fremanezumab treatment after diagnosis of EM or CM; age ≥18 years at the time of fremanezumab initiation; treatment with ≥1 dose of fremanezumab; ≥1 follow-up visit since first fremanezumab treatment initiation; and chart containing ≥2 measurements of monthly migraine days (MMD), 1 prior to first initiation of fremanezumab treatment (pre-index period) or at the index date and ≥1 during the follow-up period as an outcome assessment. Patients who were pregnant in the 12 months prior to first initiation or during fremanezumab treatment were excluded.

Outcome assessment
Patient outcomes were evaluated in subgroups of patients with physician-reported EM or CM, as well as in subgroups of patients with DTT migraine, including patients with physician-reported MO, major depressive disorder (MDD), or generalized anxiety disorder (GAD) and
patients with prior exposure to a different CGRP pathway–targeted mAb in the 12 months before first initiation of fremanezumab treatment. Although these subgroups were based on physician report, the eCRF provided physicians with the following definitions as a guide: EM, 0 to 14 monthly headache days (MHD); CM, ≥15 MHD; MO, ≥10 days per month of use of ergots, triptans, opioids, combination analgesics, or combinations of drugs of different classes not individually overused or ≥15 days per month of use of non-opioid analgesics, acetaminophen, or non-steroidal anti-inflammatory drugs. A definition of MDD or GAD was not provided but was based on diagnosis noted in the chart. Baseline MMD and MHD were collected for 1 month pre-index, baseline MDD and GAD severity were collected for 3 months pre-index, and comorbidities and prior treatments were collected for 12 months pre-index. Study outcomes were evaluated during the full follow-up period after first fremanezumab treatment initiation until treatment discontinuation or chart abstraction (i.e., post-index). Effectiveness outcomes that were evaluated during the follow-up period included change from baseline in MMD and change from baseline in MHD at each monthly time point post-index. The proportion of patients with a ≥50% reduction in MMD from baseline was also assessed at each monthly time point. For patients with MDD and GAD, respectively, MDD and GAD severity (no symptoms, mild, moderate, or severe) at baseline and the change in MDD and GAD severity (improved, no change, or worsened) post-index were assessed. Clinicians were asked to estimate the percentage of time their patients were adherent to treatment during the full period of the first treatment with a given dosage of fremanezumab. Rates of treatment adherence to fremanezumab dosing schedules were estimated as the percentage of patients complying with treatment administration schedules >80% of the time, based on those clinician assessments. Adherence, discontinuation rates, and reasons for discontinuation were reported over the full follow-up period, the duration of which varied among patients.

Statistical analysis
The study included 1003 patients, and from that total population, patients were further selected for these subgroup analyses by migraine type or presence of DTT migraine. For all subgroups, sample sizes were not based on any statistical considerations. Baseline patient demographics, disease characteristics, and treatment characteristics (including concomitant medication use) were summarized using mean (standard deviation [SD]) values for continuous variables and frequency distributions for categorical variables. For effectiveness outcomes during the follow-up period, continuous variables were summarized using descriptive statistics (mean and SD) and categorical variables were summarized using frequency distributions. For these effectiveness outcomes, results were clustered for patients with available assessments within ±15 days of each reported time point (e.g., Month 1, Month 2) due to heterogeneity in the assessment times observed in real-world practice. As a result, not all patients were included in the analyses for each time point and sample sizes varied accordingly.

Results
Clinician and patient characteristics
Of the 421 clinicians included in this study, 240 (57.0%) were neurologists, 80 (19.0%) were general practitioners, 36 (8.6%) were pain management specialists, 21 (5.0%) were psychiatrists, 38 (9.0%) were PAs or NPs, and 6 (1.4%) were other headache specialists. Clinicians had treated a mean (SD) of 367.0 (457.6) patients with migraine in the 12 months prior to the study, including 68.1 (159.2) patients treated with fremanezumab. A total of 1003 patients were included in this study, with these patients initiating fremanezumab treatment between October 2, 2018, and July 17, 2020. Of the 1003 patients included in the study, 416 (41.5%) and 587 (58.5%) patients were diagnosed with EM and CM, respectively; 220 (21.9%) patients had physician-reported MO. A total of 134 (13.4%) patients had physician-reported MDD and 120 (12.0%) patients had physician-reported GAD. Ninety-eight (9.8%) patients had been previously treated with another CGRP pathway–targeted mAb. A total of 622 (62.0%) patients were receiving monthly fremanezumab and 381 (38.0%) were receiving quarterly fremanezumab at treatment initiation. For patients taking monthly versus quarterly fremanezumab, the time from diagnosis to index date was longer (mean [SD], 7.4 [8.8] vs 5.4 [7.9] years), a higher proportion had CM (61.6% [383/1003] vs 53.5% [204/1003]), and the number of MMD and MHD at baseline was higher (mean [SD] MMD, 13.2 [6.5] vs 11.9 [6.1]; mean [SD] MHD, 14.8 [8.0] vs 12.9 [7.7]).

Baseline and demographic characteristics for the subgroups of patients with DTT migraine are summarized in Table 1. The mean (SD) age ranged from 38.5 (12.2) years in the EM subgroup to 43.0 (12.2) years in the prior CGRP pathway–targeted mAb subgroup. The mean (SD) duration of follow-up ranged from 7.0 (4.5) months in the CM subgroup to 7.6 (4.5) months in the GAD subgroup. In the prior CGRP pathway–targeted mAb subgroup, 41% of patients had failed ≥5 prior migraine preventive treatments, while only 12% to 29% of patients in the other subgroups had failed ≥5 prior preventive treatments (Table 1). Acute and preventive medications taken prior to and concomitantly with fremanezumab treatment
Table 1 Demographic and Baseline Characteristics Across Patient Subgroups

| Characteristic                              | Patients with EM (n = 416) | Patients with CM (n = 587) | Patients with MO (n = 220) | Patients with MDD (n = 134) | Patients with GAD (n = 120) | Prior CGRP exposure (n = 98) |
|--------------------------------------------|----------------------------|---------------------------|---------------------------|----------------------------|---------------------------|-----------------------------|
| Age, years, mean (SD)                      | 38.5 (12.2)                | 40.5 (12.5)               | 40.7 (12.4)               | 40.1 (10.6)                | 39.0 (11.7)               | 43.0 (12.2)                 |
| Sex, n (%)                                 |                            |                           |                           |                            |                           |                             |
| Female                                     | 301 (72.4)                 | 459 (78.2)                | 155 (70.5)                | 110 (82.1)                 | 99 (82.5)                 | 77 (78.6)                   |
| Male                                       | 115 (27.6)                 | 126 (21.5)                | 65 (29.5)                 | 24 (17.9)                  | 21 (17.5)                 | 21 (21.4)                   |
| Other                                      | 0 (0.0)                    | 2 (0.3)                   | 0 (0.0)                   | 0 (0.0)                    | 0 (0.0)                   | 0 (0.0)                     |
| Race, n (%)                                |                            |                           |                           |                            |                           |                             |
| White                                      | 317 (76.2)                 | 465 (79.2)                | 158 (71.8)                | 112 (83.6)                 | 99 (82.5)                 | 78 (79.6)                   |
| Black or African American                  | 59 (14.2)                  | 78 (13.3)                 | 42 (19.1)                 | 14 (10.4)                  | 11 (9.2)                  | 11 (11.2)                   |
| Asian                                      | 26 (6.3)                   | 30 (5.1)                  | 10 (4.5)                  | 5 (3.7)                    | 5 (4.2)                   | 1 (1.0)                     |
| Native American or American Indian         | 6 (1.4)                    | 1 (0.2)                   | 2 (0.9)                   | 0 (0.0)                    | 0 (0.0)                   | 1 (1.0)                     |
| Other                                      | 8 (1.9)                    | 12 (2.0)                  | 7 (3.2)                   | 3 (2.2)                    | 5 (4.2)                   | 6 (6.1)                     |
| Unknown                                    | 0 (0.0)                    | 1 (0.2)                   | 1 (0.5)                   | 0 (0.0)                    | 0 (0.0)                   | 1 (1.0)                     |
| Duration of follow-up, months, mean (SD)   | 7.1 (4.4)                  | 7.0 (4.5)                 | 7.1 (3.7)                 | 7.3 (4.4)                  | 7.6 (4.5)                 | 7.2 (4.7)                   |
| Baseline MMD, mean (SD)                    | 10.0 (5.1)                 | 14.7 (6.5)                | 13.4 (6.7)                | 14.5 (6.1)                 | 14.3 (6.3)                | 13.1 (6.2)                  |
| Baseline MHD, mean (SD)                    | 10.7 (6.1)                 | 164 (8.3)                 | 15.8 (8.8)                | 17.5 (8.0)                 | 16.7 (8.3)                | 14.6 (7.9)                  |
| Prior preventive treatment failures, n (%) |                            |                           |                           |                            |                           |                             |
| 0                                          | 34 (8.2)                   | 26 (4.4)                  | 1 (0.5)                   | 4 (3.0)                    | 3 (2.5)                   | 1 (1.0)                     |
| 1                                          | 54 (13.0)                  | 57 (9.7)                  | 12 (5.5)                  | 11 (8.2)                   | 9 (7.5)                   | 9 (9.2)                     |
| 2                                          | 120 (28.8)                 | 126 (21.5)                | 36 (16.4)                 | 20 (14.9)                  | 18 (15.0)                 | 17 (17.3)                   |
| 3                                          | 105 (25.2)                 | 177 (30.2)                | 62 (28.2)                 | 42 (31.3)                  | 39 (32.5)                 | 17 (17.3)                   |
| 4                                          | 52 (12.5)                  | 109 (18.6)                | 45 (20.5)                 | 22 (16.4)                  | 20 (16.7)                 | 14 (14.3)                   |
| 5                                          | 18 (4.3)                   | 38 (6.5)                  | 26 (11.8)                 | 12 (9.0)                   | 10 (8.3)                  | 12 (12.2)                   |
| ≥ 6                                        | 33 (7.9)                   | 54 (9.2)                  | 38 (17.3)                 | 23 (17.2)                  | 21 (17.5)                 | 28 (28.6)                   |
| Common baseline comorbid conditions, n (%)  |                            |                           |                           |                            |                           |                             |
| Insomnia                                   | 64 (15.4)                  | 132 (22.5)                | 65 (29.5)                 | 49 (36.6)                  | 42 (35.0)                 | 27 (27.6)                   |
| Allergies                                  | 63 (15.1)                  | 95 (16.2)                 | 38 (17.3)                 | 30 (22.4)                  | 24 (20.0)                 | 19 (19.4)                   |
| Neck pain                                  | 60 (14.4)                  | 95 (16.2)                 | 51 (23.2)                 | 26 (19.4)                  | 29 (24.2)                 | 28 (28.6)                   |
| Hypertension                               | 61 (14.7)                  | 82 (14.0)                 | 32 (14.5)                 | 26 (19.4)                  | 22 (18.3)                 | 18 (18.4)                   |
| Back pain                                  | 46 (11.1)                  | 92 (15.7)                 | 35 (15.9)                 | 20 (14.9)                  | 24 (20.0)                 | 20 (20.4)                   |
| Obesity                                    | 47 (11.3)                  | 90 (15.3)                 | 38 (17.3)                 | 37 (27.6)                  | 27 (22.5)                 | 20 (20.4)                   |
| MDD                                        | 41 (9.9)                   | 93 (15.8)                 | 47 (21.4)                 | 134 (100.0)                | 39 (32.5)                 | 22 (22.4)                   |
| GAD                                        | 27 (6.5)                   | 93 (15.8)                 | 52 (23.6)                 | 39 (29.1)                  | 120 (100.0)               | 22 (22.4)                   |
| Chronic pain                               | 32 (7.7)                   | 79 (13.5)                 | 41 (18.6)                 | 26 (19.4)                  | 34 (28.3)                 | 22 (22.4)                   |
| Asthma                                     | 38 (9.1)                   | 63 (10.7)                 | 33 (15.0)                 | 18 (13.4)                  | 20 (16.7)                 | 13 (13.3)                   |
| Clinician-estimated adherence rate, mean (SD) | 92.3 (17.6) | 95.1 (13.1) | 89.8 (19.7) | 95.0 (12.3) | 95.6 (10.0) | 95.0 (11.2) |

CGRP, calcitonin gene-related peptide; CM, chronic migraine; EM, episodic migraine; GAD, generalized anxiety disorder; MDD, major depressive disorder; MHD, monthly headache days; MMD, monthly migraine days; MO, medication overuse; SD, standard deviation

*Incidence ≥ 10% in the overall study population
are summarized in Supplemental Table 1; both acute and preventive medication use decreased after fremanezumab initiation.

Fremanezumab treatment adherence and discontinuations during the post-index period
Across the EM, the CM, and all DTT subgroups, adherence to fremanezumab treatment was high and fremanezumab treatment discontinuation rates were low after the index dose (Table 1). The majority of patients in all subgroups (≥85%) continued on their originally prescribed dosing regimen (monthly or quarterly) of fremanezumab.

Monthly migraine days and other key outcomes
Migraine type subgroups

**EM subgroup**  Among patients with EM (n = 416), the mean (SD) number of MMD at baseline was 10.0 (5.1). Mean (percent) reductions from baseline in MMD were −3.4 (34.0%) at Month 1, −4.7 (47.0%) at Month 3, and −7.7 (77.0%) at Month 6 (Fig. 1). The proportion of patients with ≥50% reduction in MMD increased from Month 1 (31.6% [31/97]) to Month 3 (52.1% [49/94]) and Month 6 (75.8% [25/33]; Fig. 2).

**CM subgroup**  In patients with CM (n = 587), the mean (SD) number of MMD at baseline was 14.7 (6.5). Mean (percent) reductions from baseline in MMD were −5.5 (37.4%) at Month 1, −7.9 (53.7%) at Month 3, and −10.1 (68.7%) at Month 6 (Fig. 1). The proportion of patients with ≥50% reduction in MMD increased from Month 1 (32.1% [43/134]) to Month 3 (58.3% [91/156]) and Month 6 (76.3% [45/59]; Fig. 2). Increasing reductions in MMD over the 6-month treatment period were observed regardless of migraine type (Figs. 1 and 2).

**MO subgroup**  In the MO subgroup (n = 220), the mean (SD) number of MMD at baseline was 13.4 (6.7). The mean (percent) reduction from baseline in MMD increased from −5.5 (41.0%) at Month 1 to −7.0 (52.2%) at Month 3 and −10.8 (80.6%) at Month 6 (Fig. 1). The proportion of patients with MO with a ≥50% reduction in MMD also increased from Month 1 (33.3% [14/42]) to Month 3 (52.1% [49/94]) and Month 6 (75.8% [25/33]; Fig. 2).

![Fig. 1](image-url)  Change from baseline in MMD across patient subgroups. BL, baseline; CGRP, calcitonin gene-related peptide; CM, chronic migraine; EM, episodic migraine; GAD, generalized anxiety disorder; mAb, monoclonal antibody; MDD, major depressive disorder; MMD, monthly migraine days; MO, medication overuse. *Number of patients with available assessment at each time point
MDD and GAD subgroups

**MDD subgroup** In the MDD subgroup \((n = 134)\), the mean (SD) number of MMD at baseline was 14.5 (6.1). Mean (percent) reductions from baseline in MMD were \(-5.4\) (37.2%) at Month 1, \(-6.8\) (46.9%) at Month 3, and \(-9.9\) (68.3%) at Month 6 (Fig. 1). The proportion of patients with a \(\geq 50\%\) reduction in MMD increased from Month 1 through Months 3 and 6 (Month 1, 36.7% [11/30]; Month 3, 44.7% [17/38]; Month 6, 81.8% [18/22]; Fig. 2).

In the MDD subgroup, the severity of MDD at baseline was reported as no symptoms for 4.5% (6/134) of patients, mild for 37.3% (50/134), moderate for 45.5% (61/134), and severe for 10.4% (14/134). MDD severity was reported as improved by 45.5% (61/134) of patients post-index (Fig. 3).

**GAD subgroup** In the GAD subgroup \((n = 120)\), the mean (SD) number of MMD at baseline was 14.3 (6.3). Mean (percent) reductions from baseline in MMD were \(-5.7\) (39.9%) at Month 1, \(-7.2\) (50.3%) at Month 3, and \(-9.5\) (66.4%) at Month 6 (Fig. 1). The proportion of patients with GAD with a \(\geq 50\%\) reduction in MMD increased from Month 1 (37.0% [10/27]) to Month 3 (53.3% [17/32]) and Month 6 (80.0% [12/15]; Fig. 2).

In this subgroup, the severity of GAD at baseline was reported as no symptoms for 1.7% (2/120) of patients, mild for 35.8% (43/120), moderate for 45.8% (55/120), and severe for 15.8% (19/120). GAD severity was
reported as improved by 45.8% (55/120) of patients with GAD post-index (Fig. 3).

Prior CGRP pathway–targeted mAb exposure subgroup
Among patients who switched from another prior CGRP pathway–targeted mAb to fremanezumab (n = 98), 92 (93.9%) provided a reason for switching to fremanezumab. The most common reasons were inadequate response to treatment (defined as no clinically meaningful improvement after ≥ 3 months of therapy; 67.4% [62/92]) and side effects (32.6% [30/92]). Other frequent reasons for switching to fremanezumab included insurance coverage (19.6% [18/92]), the option of quarterly dosing (16.3% [15/92]), availability of free samples (15.2% [14/92]), the long-acting profile of fremanezumab (14.1% [13/92]), preference indicated by the patient (14.1% [13/92]), wearing off prior to the next injection (10.9% [10/92]), and options of both quarterly and monthly dosing (10.9% [10/92]). Many patients indicated >1 reason for switching.

In the overall subgroup of patients with prior exposure to another CGRP pathway–targeted mAb, the mean (SD) number of MMD at baseline was 13.1 (6.2). Mean (percent) reductions from baseline in MMD were −2.8 (21.4%) at Month 1, −7.2 (55.0%) at Month 3, and −9.0 (68.7%) at Month 6 (Fig. 1). The proportion of patients in the prior CGRP pathway–targeted mAb subgroup with ≥50% reduction in MMD increased from Month 1 (9.1% [2/22]) to Month 3 (45.5% [10/22]) and Month 6 (63.6% [7/11]; Fig. 2).

Monthly headache days
Migraine type, MO, MDD, GAD, and prior CGRP mAb exposure subgroups
Mean (SD) numbers of MHD at baseline across all evaluated subgroups are shown in Table 1. Across all subgroups, trends in mean (percent) reductions in MHD were comparable to those shown for MMD (Fig. 4).

Discussion
There is limited real-world evidence on the use of fremanezumab for the preventive treatment of migraine, especially among patients with DTT migraine. The current clinician panel–based retrospective chart review study provides a timely and comprehensive assessment of the effectiveness of fremanezumab in a real-world setting across a variety of patient subgroups, including those with potentially DTT migraine. MMD and MHD reductions observed in the current subgroup analyses supported the effectiveness in patients with EM or CM and those with DTT migraine, based on the presence of MO, GAD, MDD, or prior CGRP pathway–targeted mAb exposure.

Regardless of the type of migraine (EM or CM), reductions from baseline in MMD and MHD were observed

![Figure 3: Change in MDD and GAD severity. GAD, generalized anxiety disorder; MDD, major depressive disorder.](image-url)
within 1 month after initiating fremanezumab treatment, with continued improvement demonstrated over 6 months of treatment. The proportion of patients with ≥50% reduction in MMD also increased from Month 1 to Month 6 of fremanezumab treatment in both the EM and CM subgroups, and discontinuation rates were low regardless of the subgroup studied. These real-world effectiveness results complement those from the randomized, double-blind, placebo-controlled, phase 3 HALO studies, which reported significant reductions in MMD with fremanezumab versus placebo over 3 months of treatment in patients with EM or CM [15, 16]. Likewise, over the course of a 12-month extension study, the proportion of patients with ≥50% reduction in MMD also increased over time and discontinuation rates were low [20]. In the randomized, double-blind, placebo-controlled, phase 3b FOCUS study, which included a similar population to the current real-world study (patients with EM or CM with inadequate response to 2 to 4 prior classes of migraine preventive treatments), patients who received fremanezumab had significant reductions in MMD compared with those assigned to placebo over 3 months of treatment and the proportion of patients with ≥50% reduction in MMD increased over an additional 3-month open-label extension [17, 21]. Compared with phase 3 trials [15–17], which showed least-squares mean changes from baseline in MMD ranging from −3.4 to −5.0 over 3 months for patients with EM or CM, the current study demonstrated even larger mean changes from baseline in MMD at 3 months in patients with EM or CM (−4.7 to −7.9), highlighting the effectiveness of fremanezumab in the real-world setting. These differences in real-world and clinical trial outcomes are in line with those observed for other CGRP pathway–targeted mAbs erenumab and galcanezumab [22–28].

The current study also demonstrated reductions in MMD and MHD with fremanezumab treatment for patients diagnosed with MO. These real-world outcomes support the findings of previous subgroup analyses of the randomized, double-blind, placebo-controlled, phase 3 HALO study in patients with MO (n = 587) [18]. In a subgroup of patients with MO from the HALO study, fremanezumab resulted in significantly greater mean reductions from baseline in MMD at Month 3 with both quarterly and monthly dosing compared with placebo, with mean changes from baseline in MMD ranging from −4.8 to −5.2 at 3 months [18]. Given that secondary headache from MO is common among patients with migraine [29], these findings from both clinical trial and real-world settings support the benefits of fremanezumab.
were inadequate response to treatment and side effects. During the post-index period, patients who had switched from a prior CGRP pathway–targeted mAb experienced substantial reductions in MMD with fremanezumab treatment during the 6-month post-index period. Only 12% of patients who received a prior CGRP pathway–targeted mAb discontinued fremanezumab treatment after the index dose, most often due to poor response. These results suggest that fremanezumab is effective and well tolerated in patients with migraine who had failed a different CGRP pathway–targeted mAb and therefore that treatment failure to 1 CGRP pathway–targeted mAb does not predict treatment failure to another. This finding supports previous evidence showing that patients who had prior failure of a CGRP pathway–targeted mAb treatment achieved a clinical benefit by switching to another CGRP pathway–targeted mAb [34–36]. In a previous retrospective cohort study by Overeem and colleagues that included 25 patients who did not respond to erenumab and switched to either galcanezumab or fremanezumab, MHD were significantly reduced by Month 3 after switching and approximately 12% of patients achieved a ≥50% reduction in MHD [36]. In the current study, in the subgroup switching to fremanezumab from another prior CGRP mAb, the proportion of patients achieving a ≥50% reduction in MMD at Month 3 (45.5%) was substantially higher; however, the patient characteristics differed from the current study, with many patients in that prior study reporting daily headache [36].

There are several strengths in the design of this study. The real-world setting of this online physician chart review closely reflects the true clinical landscape of migraine. The broad range of clinicians (e.g., neurologists, general practitioners, NPs, PAs, psychiatrists) included in this study may more accurately reflect real-world use of fremanezumab and enhance the generalizability of these results. In addition, the large patient sample size allowed for a number of subgroup analyses to be conducted, including the currently presented analyses in populations by migraine type or with DTT migraine (MO, MDD, GAD, or prior CGRP pathway–targeted mAb exposure). Furthermore, the inclusion of patients with a physician-confirmed migraine diagnosis and collection of both health care provider– and patient-reported outcomes have given a comprehensive view into the clinical outcomes across the broad population of patients with migraine. The results from this real-world study further support the effectiveness of fremanezumab as demonstrated in previous clinical trials [15–17], including in patients with DTT migraine [17–19, 30], and contribute to the real-world data on fremanezumab and other CGRP pathway–targeted mAbs [22, 24, 37–45].
This real-world study had limitations that need to be considered. Retrospective real-world studies are subject to bias and confounding factors, problems that are controlled for in randomized controlled trials. For the subgroups with MDD or GAD, the diagnosis was based only on the diagnosis noted in the chart, which was not required to be made by a qualified mental health professional and was not based on any specific definition or guidance in the current study. Thus, there is the potential that these diagnoses were not completely accurate for all patients included in those subgroups. Moreover, data collection efforts were limited by the availability of clinical data in the medical charts. With that said, observed discontinuation rates were relatively low (~8%), suggesting that discontinuation is not the cause of the limited availability of certain data. While measurements were conducted at monthly time points, it is unlikely that patients would be seen in the clinic every month, limiting availability of data at any individual month to those who came for follow-up in that month. Likewise, patients may have fewer follow-up visits if they experience a favorable therapeutic effect with fremanezumab and improvement in their symptoms. Other reasons may include physicians’ lack of reporting of the outcomes assessed at the follow-up appointments or the possibility that these follow-ups were not conducted in person. Although adherence to treatment, discontinuation rates, and reasons for discontinuation were reported over the full follow-up period, the length of this time frame varied among patients. As noted in the statistical analysis section, effectiveness outcomes clustered patients with available assessments within ±15 days of each time point reported (e.g., Month 1, Month 2) due to heterogeneity in the assessment times observed in real-world practice. As a result, not all patients were included in the analyses for each time point and sample sizes varied accordingly. In addition, the mean follow-up period of 7 months was relatively short, with effectiveness outcomes evaluated over 6 months due to low follow-up numbers at later time points. Reporting rates declined over the course of the study; however, this decrease over time in the proportion of patients who responded to each outcome was not necessarily due to discontinuation of treatment, as described previously. In addition, certain outcomes that may have been of interest for some of the subgroups, including detoxification prior to initiating fremanezumab or the proportion of patients reverting from MO to no MO with fremanezumab treatment in the MO subgroup, were not collected in the eCRF. In line with real-world clinical practice, some patients in the current study were using concomitant preventive medications with fremanezumab, which could potentially have had an impact on observed effectiveness outcomes; however, preventive medication use decreased after fremanezumab initiation. MMD and MHD also decreased substantially after fremanezumab initiation, indicating that the addition of fremanezumab treatment led to improvements in both outcomes. Furthermore, approximately 20% of patients in the HALO CM pivotal study were using concomitant preventive medication [15]; efficacy, including reduction in MHD, was comparable in subgroups of patients from HALO CM with and without preventive medication use [46].

Conclusions
Sustained reductions in MMD and MHD and clinically meaningful (≥50%) reductions in MMD were observed, with consistent effectiveness results across subgroups of patients with EM or CM and those with DTT migraine, including patients with acute MO, comorbid MDD, comorbid GAD, and prior exposure to another CGRP pathway–targeted mAb. Taken together, the results from this real-world study reinforce the effectiveness of fremanezumab as a migraine preventive treatment across the full spectrum of patients with migraine, including those with comorbidities or other factors that may contribute to DTT migraine.

Abbreviations
BL: Baseline; CGRP: Calcitonin gene-related peptide; CM: Chronic migraine; DTT: Difficult-to-treat; eCRF: Electronic case report form; EM: Episodic migraine; GAD: Generalized anxiety disorder; mAb: Monoclonal antibody; MDD: Major depressive disorder; MHD: Monthly headache days; MMD: Monthly migraine days; MO: Medication overuse; SD: Standard deviation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10194-022-01415-x.

Additional file 1.

Acknowledgments
Editorial assistance was provided by Lisa Shannon, PhD, of Cello Health Communications/MedErgy (Yardley, PA), which was in accordance with Good Publication Practice (GPP3) guidelines and funded by Teva Pharmaceuticals. The authors maintained full editorial control of the manuscript and the decision to submit it for publication.

Authors’ contributions
O.P.-L., T.I.T., R.S., E.Y., F.M., and R.A. participated in the study design, summarization, and interpretation of results. T.I.T. coordinated the data collection. O.P.-L., R.S., and E.Y. conducted the data analysis. All authors participated in the critical review of the manuscript and approved the final manuscript for submission.

Funding
This study was funded by Teva Pharmaceuticals.

Availability of data and materials
All data for the analyses presented in this manuscript are included in this published article and its supplementary information files.
Driessen et al. The Journal of Headache and Pain (2022) 23:56

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
M.T.D., S.F.T., M.J.S., and K.C. are employees of Teva Pharmaceuticals. J.M.C. is a former employee of Teva Pharmaceuticals. O.P.L., T.T., R.S., E.Y., F.M., and R.A. are employees of Analysis Group, which performed these analyses funded by Teva Pharmaceuticals.

Author details
1 Teva Pharmaceuticals, Piet Heinkade 107, 1019 BR Amsterdam, The Netherlands. 2 Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA. 3 Teva Pharmaceuticals, Parsippany, NJ, USA. 4 Analysis Group, Boston, MA, USA.

Received: 6 January 2022 Accepted: 15 March 2022
Published online: 16 May 2022

References
1. Burch R, Rizzioli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 58(4):496–505. https://doi.org/10.1111/head.13281
2. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
3. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19(1):17. https://doi.org/10.1186/s10194-018-0907-6
4. Vo P, Fang J, Biltou A, Laflamme AK, Gupta S (2018) Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. https://doi.org/10.1186/s10194-018-0907-6
5. Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W, Jackson S et al (2020) A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient Rep Outcomes 4(1):53. https://doi.org/10.1186/s41687-020-00221-w
6. Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB (2013) Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health 16(1):31–38. https://doi.org/10.1016/j.jval.2012.08.2212
7. Hunter P (2016) New migraine therapies promise prevention: a new generation of drugs could avert migraine attacks rather than merely relieve symptoms. EMBO Rep 17(6):797–799. https://doi.org/10.15252/embr.201642519
8. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC et al (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 13(8):615–624. https://doi.org/10.1007/s10194-012-0479-9
9. Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 Migraine in America Symptoms and Treatment (MAST) study. J Headache Pain 19(1):38. https://doi.org/10.1186/s10194-018-0860-z
10. Bogle ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8):1157–1168. https://doi.org/10.1111/j.1526-4610.2008.01217.x
11. Lipton RB, Iyer R, Cohen J, Jackson J, Ramirez-Campos V, Cotton S et al (2019) Burden of comorbid depression and anxiety on migraine-specific health-related quality of life in adult migraine patients in the United States. Value Health 22(Suppl 3):S756. https://doi.org/10.1016/j.val.2019.09.1872
12. Lipton RB, Seng EK, Chu MK, Reed ML, Fanning KM, Adams AM et al (2020) The effect of psychiatric comorbidities on headache-related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 60(8):1683–1696. https://doi.org/10.1111/head.13914
13. Newman L, Vo P, Zhou L, Lopez Lopez C, Cheadle A, Olson M et al (2021) Health care utilization and costs in patients with migraine who have failed previous preventive treatments. Neurol Clin Pract 11(3):206–215. https://doi.org/10.1212/CNP.0000000000001076
14. AJOVY (2020) AJOVY (fremanezumab-vfrm) [prescribing information]. North Wales (PA): Teva Pharmaceuticals USA, Inc. Revised 2020. Available from: https://www.aiovyhcp.com/globalassets/ajo/ajojy-pj.pdf
15. Silberstein SD, Dodick DW, Bogle ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122. https://doi.org/10.1056/NEJMoa1709038
16. Dodick DW, Silberstein SD, Bogle ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853
17. Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030–1040. https://doi.org/10.1016/S0140-6736(19)31946-4
18. Silberstein SD, Cohen JM, Seminero MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https://doi.org/10.1186/s10194-020-01173-8
19. Lipton RB, Cohen JM, Galic M, Seminero MJ, Yeung PP, Aycardi E et al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61(4):662–672. https://doi.org/10.1111/head.14097
20. Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95(18):e2487–e2499. https://doi.org/10.1212/WNL.00000000000010680
21. Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X et al (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain 22(1):68. https://doi.org/10.1186/s10194-021-01279-7
22. Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giambardino MA et al (2020) Long-term effectiveness of galcanezumab in the treatment of episodic and chronic migraine. Cephalalgia 40(6):543–553. https://doi.org/10.1177/03331024209788347
23. Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ et al (2020) Efficacy and safety of fremanezumab in chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health 23(3):31–38. https://doi.org/10.1016/j.jval.2020.08.2212
24. Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2018) Efficiency and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38(10):1611–1621. https://doi.org/10.1177/0333102418798839
25. Ashina M, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2019) Efficacy of erenumab for the prevention of chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 39(10):1611–1621. https://doi.org/10.1177/0333102419851087
26. Vernieri F, Altamura C, Aurilia C, Brunelli N, Egozi G, Forlì L et al (2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients
with migraine in Italy (the GARLIT study). Neurol Sci 41(Suppl 2):487–488. https://doi.org/10.1007/s10072-020-04669-y

28. Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S et al (2021) Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers. Neurol Ther. https://doi.org/10.1007/s40120-021-00245-4

29. Alstadhaug KB, Ofte HK, Kristoffersen ES (2017) Preventing and treating medication overuse headache. Pain Rep 2(4):e612. https://doi.org/10.1097/PR9.0000000000000612

30. Lipton R, Cohen J, Yeung PP, Yang R, Ning X, Buse D (2019) Long-term efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression (P1.10–024). Neurology 92(Suppl 15):P1.10–024

31. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM (2003) Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 60(8):1308–1312. https://doi.org/10.1212/01.wnl.0000058907.41080.5d

32. Smitherman TA, Kolvias ED, Bailey JR (2013) Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache 53(1):23–45. https://doi.org/10.1111/head.12004

33. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260(8):1960–1969. https://doi.org/10.1007/s00415-012-6725-x

34. Ziegeler C, May A (2020) Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 60(2):469–470. https://doi.org/10.1111/head.13729

35. Porta-Etessam J, Gonzalez-Garcia N, Guerrero AL, Garcia-Azorin D (2021) Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurology (Engl Ed) 36(8):638–640. https://doi.org/10.1016/j.nrleng.2020.10.008

36. Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 13:33331024211048765. https://doi.org/10.1177/03331024211048765

37. Lambru G, Hill B, Murphy M, Tyllova J, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https://doi.org/10.1186/s10194-020-01127-0

38. Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511–1522. https://doi.org/10.1177/0333102420946725

39. Alex A, Vaughn C, RayHill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 60(10):2454–2462. https://doi.org/10.1111/head.13956

40. Barbanti P, Aurilia C, Cevoli S, Egeo G, Foﬁ L, Messina R et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real-world: results of the EARLY 2 study. Headache 61(9):1351–1363. https://doi.org/10.1111/head.14194

41. Barbanti P, Aurilia C, Egeo G, Foﬁ L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363–372. https://doi.org/10.1111/head.14032

42. Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https://doi.org/10.1186/s10194-021-01247-1

43. Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29(4):1198–1208. https://doi.org/10.1111/ene.15197

44. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther 10(2):809–826. https://doi.org/10.1007/s40122-021-00264-x

45. Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2021) Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother 35(1):1–6. https://doi.org/10.18294/JPCCP.2020.182949

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions